Global Non-Small Cell Lung Cancer Clinical Trial Pipeline Highlights, 2019 Report – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Global
Non-Small Cell Lung Cancer Clinical Trial Pipeline Highlights – 2019”
report has been added to ResearchAndMarkets.com’s
offering.

Non-Small Cell Lung Cancer Pipeline Highlights – 2019, provides most
up-to-date information on key pipeline products in the global Non-Small
Cell Lung Cancer market. It covers emerging therapies for Non-Small Cell
Lung Cancer in active clinical development stages including early and
late stage clinical trials. The pipeline data presented in this report
helps executives for tracking competition, identifying partners,
evaluating opportunities, formulating business development strategies,
and executing in-licensing and out-licensing deals.

Clinical Trial Stages:

The report provides Non-Small Cell Lung Cancer pipeline products by
clinical trial stages including both early and late stage development –
phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical
trials, preclinical research, and discovery stage.

Drug Mechanism Classes:

The report provides Non-Small Cell Lung Cancer pipeline products by
their dominant mechanism of action/drug class. This helps executives
categorize products based on their drug class and also assess the
strengths and weaknesses of compounds.

Company:

The report provides Non-Small Cell Lung Cancer pipeline products by the
company.

Short-term Launch Highlights:

Find out which Non-Small Cell Lung Cancer pipeline products will be
launched in the US and Ex-US till 2024.

Summary:

• Non-Small Cell Lung Cancer phase 3 clinical trial pipeline products
• Non-Small Cell Lung Cancer phase 2 clinical trial pipeline products
• Non-Small Cell Lung Cancer phase 1 clinical trial pipeline products
• Non-Small Cell Lung Cancer preclinical research pipeline products
• Non-Small Cell Lung Cancer discovery stage pipeline products
• Non-Small Cell Lung Cancer pipeline products short-term launch
  highlights

Key Topics Covered:

1. Non-Small Cell Lung Cancer Pipeline by Stages

2. Non-Small Cell Lung Cancer Phase 3 Clinical Trial Insights

3. Non-Small Cell Lung Cancer Phase 2 Clinical Trial Insights

4. Non-Small Cell Lung Cancer Phase 1 Clinical Trial Insights

5. Non-Small Cell Lung Cancer Preclinical Research Insights

6. Non-Small Cell Lung Cancer Discovery Stage Insights

7. Appendix

8. Research Methodology

For more information about this report visit https://www.researchandmarkets.com/r/pqnhyr

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Lung
Cancer Drugs, Clinical
Trials